Printer Friendly

Afamelanotide improves erythropoietic protoporphyria.

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Afamelanotide reduces the number and severity of phototoxic reactions, shortens recovery time, and markedly improves disease-related quality of life in adults who have erythropoietic protoporphyria, according to a report in the New England Journal of Medicine.

Erythropoietic protoporphyria (EPP), a rare inborn error of metabolism that usually manifests in early childhood as severe photosensitivity, causes excruciating pain 1-20 minutes after exposure to the sun.

Usually, symptoms subside in 12-24 hours. Blistering and scarring occur in other types of cutaneous porphyria but are unusual in EPP.

The disorder has a major impact on patients' quality of life, drastically limiting their daily activities, work opportunities, and lifestyle choices. There is no effective treatment. Many therapies have been attempted, but all have shown little or no benefit, said Dr. Janneke G. Langendonk, of Erasmus Medical Center, Rotterdam, the Netherlands, and her associates.

Afamelanotide is an analogue of human alpha-melanocyte-stimulating hormone approved for EPP on a compassionate-use basis in Italy and Switzerland for over 8 years.

Two multicenter, randomized, double-blind, placebo-controlled phase III trials were performed in adults in Europe (74 patients) and the United States (93 patients).

Participants in these industry-sponsored studies received active or placebo subcutaneous implants in the fat above the iliac crest at baseline and on days 60 and 120 in the United States, and also on days 180 and 240 in Europe.

The primary efficacy end point in both studies--the duration of pain-free exposure to sunlight--was 70% longer in the U.S. trial in patients who received active treatment (median, 69 hours) than in those who received placebo (median, 41 hours).

The difference was even greater in the European patients (6 hours vs. 0.8 hours). Afamelanotide halved the number of phototoxic reactions in the European trial (77 vs. 146), but did not reduce the number of reactions in the U.S. trial.

"In both studies, placebo recipients tended to have more pain relative to the time spent in direct sunlight, and they had more days with moderate to severe pain," the investigators said (N Engl J Med. 2015;373:48-59).

Afamelanotide also shortened recovery time from phototoxic reactions, a major benefit because these reactions can last for several days and cause frequent absences from school or work. The active treatment also markedly improved every aspect of patients' quality of life, as measured by the Erythropoietic Protoporphyria Quality-of-Life questionnaire.

Based on these results, "the European Medicines Agency and the European Commission recently approved the use of afamelanotide in patients with confirmed erythropoietic protoporphyria," the researchers noted.

dermnews@frontlinemedcom.com

COPYRIGHT 2015 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:MEDICAL DERMATOLOGY
Author:Moon, Mary Ann
Publication:Dermatology News
Article Type:Report
Geographic Code:1USA
Date:Oct 1, 2015
Words:427
Previous Article:Red gums raise red flag in oral lichen planus.
Next Article:New treatments explored for prurigo nodularis.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters